

22nd January, 2025

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Press Release – Piramal Critical Care Announces U.S. Launch of Chlorpromazine Hydrochloride for Injection, USP

Dear Sir / Madam,

This is to inform you that the Piramal Critical Care ('PCC') Division of the Company has today announced the U.S. launch of Chlorpromazine Hydrochloride for Injection, USP. With this launch, PCC continues to expand its generic injectables portfolio.

A copy of Press Release in this regard is enclosed for your ready reference.

Kindly take the above on record.

Yours truly,
For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary
Encl.: a/a

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com

Piramal Critical Care Announces U.S. Launch of Chlorpromazine Hydrochloride for Injection, USP

Bethlehem, PA – January 22, 2025: Piramal Critical Care (PCC), a division of Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), today, announced the U.S. launch of Chlorpromazine Hydrochloride for Injection, USP, which will be offered in 25mg/1mL and 50mg/2 mL vials. With this launch, PCC continues to expand their generic injectables portfolio.



Peter DeYoung, Chief Executive Officer, Piramal Global Pharma commented: “We are excited to launch Chlorpromazine Hydrochloride for Injection, USP, which joins our growing US portfolio of injectable products at Piramal Critical Care. It further complements our market-leading inhaled anesthesia products, as we strive to deliver critical care solutions to patients and healthcare providers around the world.”

The launch of Chlorpromazine Hydrochloride for Injection, USP (25mg/1mL and 50mg/2 mL vials) is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market. In 2024, PCC launched the first to market generic of Edaravone IV Infusion, which followed 2023 launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further enhance their wide portfolio of critical care products. For full prescribing information on Chlorpromazine Hydrochloride, please click here: [Full prescribing information available here.](#)

About Piramal Critical Care:

Piramal Critical Care (PCC) is a global leader in anesthesia, pain management, and intrathecal therapy. Piramal Critical Care maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world. Their product portfolio includes inhaled anesthetics, intrathecal treatments for spasticity and pain management, plasma volume expanders, and a variety of other injectables and generics. Piramal Critical Care has strong manufacturing and process development capabilities with state-of-the-art manufacturing facilities in Bethlehem, Pennsylvania, United States, Digwal, India, and Dahej, India with global regulatory accreditations and adherence to strict GMP regulations. In addition, Piramal Critical Care partners with leading pharmaceutical development and manufacturing organizations around the world.

For more information visit <http://www.PiramalCriticalCare.us> | [LinkedIn](#)

About Piramal Pharma Ltd:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private



Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information visit: [Piramal Pharma | LinkedIn](#)

For queries:

Madiha Vahid
Lead – Media & PR
Madiha.Vahid@piramal.com

Gagan Borana
Investor Relations & Enterprise Risk Management
Gagan.borana@piramal.com

*Includes one facility through minority investment in Yapan Bio